CN101570575B - Sncg的单克隆抗体及其应用 - Google Patents
Sncg的单克隆抗体及其应用 Download PDFInfo
- Publication number
- CN101570575B CN101570575B CN 200810105770 CN200810105770A CN101570575B CN 101570575 B CN101570575 B CN 101570575B CN 200810105770 CN200810105770 CN 200810105770 CN 200810105770 A CN200810105770 A CN 200810105770A CN 101570575 B CN101570575 B CN 101570575B
- Authority
- CN
- China
- Prior art keywords
- sncg
- monoclonal antibody
- level
- test kit
- tumour
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101150003802 Sncg gene Proteins 0.000 title description 7
- 102100025615 Gamma-synuclein Human genes 0.000 claims abstract description 237
- 101000787273 Homo sapiens Gamma-synuclein Proteins 0.000 claims abstract description 237
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 104
- 230000014509 gene expression Effects 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 61
- 238000001514 detection method Methods 0.000 claims abstract description 54
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 28
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 24
- 238000004393 prognosis Methods 0.000 claims abstract description 23
- 238000003745 diagnosis Methods 0.000 claims abstract description 17
- 238000004321 preservation Methods 0.000 claims abstract description 8
- 210000001124 body fluid Anatomy 0.000 claims abstract description 6
- 239000010839 body fluid Substances 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 97
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 84
- 210000002966 serum Anatomy 0.000 claims description 74
- 210000004027 cell Anatomy 0.000 claims description 54
- 210000001519 tissue Anatomy 0.000 claims description 46
- 238000012360 testing method Methods 0.000 claims description 41
- 238000003118 sandwich ELISA Methods 0.000 claims description 29
- 206010006187 Breast cancer Diseases 0.000 claims description 17
- 208000026310 Breast neoplasm Diseases 0.000 claims description 17
- 238000002965 ELISA Methods 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 238000012544 monitoring process Methods 0.000 claims description 13
- 238000012151 immunohistochemical method Methods 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 11
- 206010033128 Ovarian cancer Diseases 0.000 claims description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
- 244000005700 microbiome Species 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 10
- 238000013016 damping Methods 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000001574 biopsy Methods 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 abstract description 13
- 238000011161 development Methods 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 3
- 230000001900 immune effect Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 206010027476 Metastases Diseases 0.000 abstract description 2
- 230000009401 metastasis Effects 0.000 abstract description 2
- 238000011337 individualized treatment Methods 0.000 abstract 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 43
- 239000012634 fragment Substances 0.000 description 25
- 230000002980 postoperative effect Effects 0.000 description 19
- 230000000975 bioactive effect Effects 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 230000004083 survival effect Effects 0.000 description 13
- 238000005406 washing Methods 0.000 description 13
- 208000029742 colonic neoplasm Diseases 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 238000000197 pyrolysis Methods 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 7
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 7
- 238000001114 immunoprecipitation Methods 0.000 description 7
- 102100026882 Alpha-synuclein Human genes 0.000 description 6
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 230000009465 prokaryotic expression Effects 0.000 description 6
- 102100025617 Beta-synuclein Human genes 0.000 description 5
- 208000005189 Embolism Diseases 0.000 description 5
- 101000787265 Homo sapiens Beta-synuclein Proteins 0.000 description 5
- 238000000105 evaporative light scattering detection Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 201000011531 vascular cancer Diseases 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 238000003365 immunocytochemistry Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 101150066516 GST gene Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- -1 TMB (TMB) Chemical compound 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000001358 Pearson's chi-squared test Methods 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 102000019355 Synuclein Human genes 0.000 description 1
- 108050006783 Synuclein Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 102000007739 porin activity proteins Human genes 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000012409 standard PCR amplification Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810105770 CN101570575B (zh) | 2008-04-30 | 2008-04-30 | Sncg的单克隆抗体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810105770 CN101570575B (zh) | 2008-04-30 | 2008-04-30 | Sncg的单克隆抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101570575A CN101570575A (zh) | 2009-11-04 |
CN101570575B true CN101570575B (zh) | 2012-02-29 |
Family
ID=41230070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200810105770 Active CN101570575B (zh) | 2008-04-30 | 2008-04-30 | Sncg的单克隆抗体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101570575B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102586407A (zh) * | 2011-01-12 | 2012-07-18 | 上海交通大学医学院附属新华医院 | 一种sncg基因在乳腺癌的诊断和激素治疗中的应用 |
US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
JP7136790B2 (ja) | 2017-02-17 | 2022-09-13 | ブリストル-マイヤーズ スクイブ カンパニー | アルファ-シヌクレインに対する抗体およびその使用 |
CN109490542A (zh) * | 2017-09-11 | 2019-03-19 | 博尔诚(北京)科技有限公司 | γ突触核蛋白的胶体金检测装置及其制备方法和用途 |
CN110684107B (zh) * | 2018-07-06 | 2021-03-23 | 中国人民解放军第四军医大学 | 抗MG7-Ag的单克隆抗体(MGd1)及其用途 |
CN110684108B (zh) * | 2018-07-06 | 2021-06-04 | 中国人民解放军第四军医大学 | 抗MG7-Ag的单克隆抗体(CEA37)及其用途 |
CN111487414A (zh) * | 2019-01-29 | 2020-08-04 | 北京现代高达生物技术有限责任公司 | 一种SNCG/SCC-Ag联检胶体金试纸条及其制备方法和用途 |
CN111487415A (zh) * | 2019-01-29 | 2020-08-04 | 北京现代高达生物技术有限责任公司 | 一种sncg/nmp22联检胶体金试纸条及其制备方法和用途 |
CN111487406A (zh) * | 2019-01-29 | 2020-08-04 | 北京现代高达生物技术有限责任公司 | 一种γ突触核蛋白(SNCG)的胶体金试纸条及其制备方法和用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1723878A (zh) * | 2004-07-19 | 2006-01-25 | 中国科学院上海生命科学研究院 | 多酚及其氧化物的应用 |
CN1752104A (zh) * | 2004-09-21 | 2006-03-29 | 北京市肿瘤防治研究所 | 突触蛋白γ的单克隆抗体及其应用 |
CN101052417A (zh) * | 2004-08-09 | 2007-10-10 | 艾兰制药公司 | 突触核蛋白病以及淀粉样变性病的预防和治疗 |
-
2008
- 2008-04-30 CN CN 200810105770 patent/CN101570575B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1723878A (zh) * | 2004-07-19 | 2006-01-25 | 中国科学院上海生命科学研究院 | 多酚及其氧化物的应用 |
CN101052417A (zh) * | 2004-08-09 | 2007-10-10 | 艾兰制药公司 | 突触核蛋白病以及淀粉样变性病的预防和治疗 |
CN1752104A (zh) * | 2004-09-21 | 2006-03-29 | 北京市肿瘤防治研究所 | 突触蛋白γ的单克隆抗体及其应用 |
Non-Patent Citations (1)
Title |
---|
李尧华等.揭示a-突触核蛋白与帕金森病的关系:a-突触核蛋白.《中国临床康复》.2005,第9卷(第1期),44-47. * |
Also Published As
Publication number | Publication date |
---|---|
CN101570575A (zh) | 2009-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101570575B (zh) | Sncg的单克隆抗体及其应用 | |
US9840551B2 (en) | Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof | |
US20080118935A1 (en) | Methods and compositions for diagnosing neoplastic disease | |
US20220153865A1 (en) | Synthetic peptide, relative artificial antigen, relative anti-ehd2 antibody and preparation method thereof and use thereof | |
CN101949935A (zh) | He4单抗、多抗制备及相关诊断试剂盒研制 | |
Dou et al. | Antibody-sandwich ELISA analysis of a novel blood biomarker of CST4 in gastrointestinal cancers | |
CN101290318B (zh) | 一种用于诊断肝癌的elisa试剂盒 | |
US8357494B2 (en) | Anti-clusterin oligoclonal antibodies for diagnosis and prediction of the aggressiveness of tumours, diagnostic method and related kits | |
CN102782500B (zh) | 胃癌检测用的标志物和胃癌检测方法 | |
CN103765220B (zh) | 大肠癌或食道癌的检测用标志物和检查方法 | |
CN103694332B (zh) | 一种新的肿瘤标志物 | |
KR101777259B1 (ko) | En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 | |
CN102782499B (zh) | 胃癌检测用的标志物和胃癌检测方法 | |
KR20150129932A (ko) | 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트 | |
CN104945496B (zh) | 一种多肽及其在制备与纯化对ehd2特异的抗体中的应用 | |
CN103842503A (zh) | 上皮性卵巢癌标志物检测用抗体和上皮性卵巢癌判定方法 | |
CN105037534B (zh) | 一种检测肺癌标志物myc抗原表位氨基酸序列及应用 | |
CN1752104B (zh) | 突触蛋白γ的单克隆抗体及其应用 | |
CN101514230B (zh) | Ard1的单克隆抗体及其应用 | |
CN104945506A (zh) | 一种用于乳腺癌诊断和预后判断的免疫组化试剂 | |
CN103983784B (zh) | 一种dab2ip蛋白的elisa检测方法 | |
EP3102600A1 (en) | Composition and method for detecting malignant neoplastic disease | |
CN110079506B (zh) | 一种人血清纤维胶凝蛋白ficolin-2的单克隆抗体及其应用 | |
CN102532317B (zh) | Pes1的单克隆抗体及其应用 | |
KR101594287B1 (ko) | 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BAISHILIAN INNOVATION MEDICAL TECHNOLOGY (BEIJING) Free format text: FORMER OWNER: BEIJING INST. OF TUMOR PREVENTION + CURE Effective date: 20140717 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100036 HAIDIAN, BEIJING TO: 100176 DAXING, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140717 Address after: 100176, No. 17, building 67, building 2, North View Garden, Beijing economic and Technological Development Zone, Beijing, 1717 Patentee after: BAISHILIAN INNOVATIVE MEDICAL TECHNOLOGY (BEIJING) CO.,LTD. Address before: 100036 Beijing city Haidian District Fuchengmen Road No. 52 Patentee before: BEIJING INSTITUTE FOR CANCER RESEARCH |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160929 Address after: 100176 3 floor, building 18, Hongda South Road, Beijing economic and Technological Development Zone, Beijing, 10 Patentee after: BIOCHAIN (BEIJING) SCIENCE & TECHNOLOGY Co.,Ltd. Address before: 100176, No. 17, building 67, building 2, North View Garden, Beijing economic and Technological Development Zone, Beijing, 1717 Patentee before: BAISHILIAN INNOVATIVE MEDICAL TECHNOLOGY (BEIJING) CO.,LTD. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20230523 Address after: 100176 No.18, Hongda South Road, Beijing Economic and Technological Development Zone, Daxing District, Beijing Patentee after: BIOCHAIN (BEIJING) SCIENCE & TECHNOLOGY Co.,Ltd. Patentee after: BEIJING XIANDAI GAODA BIOTECHNOLOGY Co.,Ltd. Address before: 100176 10th floor, building 3, yard 18, Hongda South Road, Beijing Economic and Technological Development Zone, Beijing Patentee before: BIOCHAIN (BEIJING) SCIENCE & TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right |